Literature DB >> 17102111

Treatment of bilateral pheochromocytoma and adrenal medullary hyperplasia.

Svante Jansson1, Amir Khorram-Manesh, Ola Nilsson, Lars Kölby, Lars-Erik Tisell, Bo Wängberg, Håkan Ahlman.   

Abstract

The risk for bilateral tumors and long-term outcome after conservative cortical-sparing adrenal surgery was studied in a consecutive single-center series. One hundred fifty-four patients were operated on (1950-2004) for pheochromocytoma (PC=137), or abdominal paraganglioma (PG=17). Twenty had MEN 2 (16 MEN 2A; 4 MEN 2B), 15 von Recklinghausen's disease (VRD), and 1 von Hippel-Lindau (VHL) disease. Twelve patients had, or developed, bilateral adrenal medullary tumors; four with MEN 2A, four with MEN 2B, three with VRD, and one with probably hereditary PC associated with brain tumors/meningioma. Two patients with MEN 2B and one with MEN 2A with had bilateral adrenalectomy (adx). Three VRD patients, two MEN 2B and one MEN 2A patients had cortical-sparing surgery. Two patients were operated on unilaterally, but developed small contralateral tumors; one of these (MEN 2A) had a second asymptomatic PC diagnosed at an older age, so surgery was withheld; the other patient (hereditary PC syndrome) had a small contralateral PC diagnosed at autopsy 9 years later. Only three of nine patients with bilateral operations needed corticosteroid replacement after surgery. Four of six patients died of associated tumors (MTC and meningioma). The mean follow-up was 13 (1-25) years. Twelve MEN 2A patients with unilateral adx have been followed up for 20 (4-36) years without developing a second PC. Cortical-sparing adrenal surgery can safely be performed in the majority of patients with bilateral PC. On the basis of our long-term experience of MEN 2A we perform contralateral adrenal resection only if a second PC is confirmed. Five patients underwent adrenal exploration because of clinical and biochemical findings compatible with PC. Four had asymmetrical positive MIBG scans. They all underwent unilateral adx and diffuse medullary hyperplasia was confirmed (medullary weight estimated morphometrically to 1.0-3.4 g vs. normal weight 0.3-0.5 g in matched controls). These patients have been followed for 19 (5-27) years with normal clinical and biochemical findings. In this rare condition removal of the largest adrenal seems adequate.

Entities:  

Mesh:

Year:  2006        PMID: 17102111     DOI: 10.1196/annals.1353.046

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

1.  Minimally invasive cortical-sparing surgery for bilateral pheochromocytomas.

Authors:  Pier Francesco Alesina; Jakob Hinrichs; Beate Meier; Kurt W Schmid; Hartmut P H Neumann; Martin K Walz
Journal:  Langenbecks Arch Surg       Date:  2011-09-21       Impact factor: 3.445

Review 2.  [Adrenalectomy for preservation of adrenocortical function. Indication and results].

Authors:  M K Walz
Journal:  Chirurg       Date:  2009-02       Impact factor: 0.955

Review 3.  Multiplicity of hormone-secreting tumors: common themes about cause, expression, and management.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2013-06-14       Impact factor: 5.958

4.  Diagnosis and treatment of adrenal medullary hyperplasia: experience from 12 cases.

Authors:  Lu Yang; Liang Gao; Xiao Lv; Shengqiang Qian; Siyuan Bu; Qiang Wei; Jiuhong Yuan; Tianyong Fan
Journal:  Int J Endocrinol       Date:  2014-08-27       Impact factor: 3.257

5.  The collection of five interesting cases of adrenal tumors from one medical center.

Authors:  Anna Babinska; Rafał Peksa; Renata Swiątkowska-Stodulska; Krzysztof Sworczak
Journal:  World J Surg Oncol       Date:  2014-12-08       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.